Visiongain Publishes Cancer Supportive Care Drugs Market Report 2020-2030

02 August 2020
Pharma

Visiongain has launched a new pharma report Cancer Supportive Care Drugs Market Report 2020-2030: Prospects by Drug Class (G-CSFs, Erythropoietin Stimulating Agents (ESA), Antiemetics, Bisphosphonates, Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Others), Type (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, Other Cancers), and Geography.

The global cancer supportive care drugs market is projected to grow at a lucrative CAGR of xx% and anticipated to surpass USD xx billion by 2030.

Supporting treatment for cancer, also known as palliative care, focuses on relieving patients from cancer therapy side effects. Supporting medications are used in cancer palliative care to reduce the side effects of cancer treatments. Treatments for cancer need to be discontinued in many cases or doses need to be decreased due to various reasons such as low numbers of blood cells. In such cases, cancer-friendly drugs such as CSFs allow patients to continue cancer therapies as well as in other cases, allowing higher doses of cancer therapies.

Cancer has been primarily leading causes of death worldwide and most treatments for cancer come with various side effects such as pain, fatigue, anxiety, issues with fertility, sexual problems, heartburn, and bone disease among other side effects. With such side effects, during cancer treatments, it is best to use supportive care medications. These factors are expected to drive the demand for cancer supportive care drugs over the forecast period.

There were approximately 18 million new cancer cases and approximately 9 million deaths reported globally in 2018, according to the World Health Organization. Also, statistics report increasing cancer prevalence over the years. This has resulted in an increase in the number of cancer therapies among patients.

Supporting drugs for cancer care are used to reduce the side effects of cancer therapy. Increasing cancer prevalence can, therefore, be directly linked to this market's growth. Increasing disposable income and improved healthcare structure have also helped people access the medicines that support cancer care.

Technological advances, however, are being adopted at a faster rate in targeted therapy drugs that have fewer side effects than traditional cancer therapy drugs. This has had a direct impact on the development of the market. However, stringent regulatory processes are anticipated to impede the market growth.

In the year 2018, North America dominated the cancer supportive care drugs by capturing over 35% of global market share. The dominance of the North American region is attributed to growing cancer prevalence cases in the region. As per the reports of the National Cancer Institute, approximately 1.7 million fresh cancer cases were diagnosed in the United States and 609,640 people died from the disease. Moreover, as per the latest edition of Canadian Cancer Statistics 2019; an estimated 220,440 cancer cases were diagnosed in 2019 out of which lung cancer was the most commonly diagnosed cancer. The growing cancer cases in the United States and Canada are anticipated to lead to a burden on the overall population, hence the US and Canadian healthcare system is spending heavily on treatment and research in the oncology field.

Furthermore, the Asia Pacific region is anticipated to grow with the highest CAGR over the forecast period owing to the growing patient pool, rising cancer incidence, and penetration of major pharmaceutical & biotech companies in emerging economies of Japan, China & India.

Some of the major players operating in this industry are AbbVie Inc., Acacia Pharma, Amgen, Apr Applied Pharma Science Research, Astellas Pharma Inc., AstraZeneca PLC, Baxter International, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche LTD., Fagron Group., Johnson & Johnson, Kyowa Hakko Kirin, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceuticals Industries among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Dermatological Drugs Market Report 2021-2031

The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.

18 January 2021

Read

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

Read

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

Read

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever